ClinicalTrials.gg
CompletedNCT05486416Updated Oct 10, 2025Results posted

Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery

A Phase 3 interventional study of HSK3486 and Propofol in General Anesthesia, sponsored by Haisco-USA Pharmaceuticals, Inc.. Completed at 28 sites in 3 countries. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Haisco-USA Pharmaceuticals, Inc. (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
465
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous [IV] slow injection over 30 [±5] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to Propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 [±5] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.

Read the detailed description

This is a global multicenter, randomized, double-blinded, propofol-controlled, phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery with endotracheal intubation.

After screening, eligible subjects will be randomized in a 2:1 ratio to receive either HSK3486 0.4/0.2 mg/kg (i.e., 0.4 mg/kg IV slow injection over 30 [±5] seconds followed by an additional 0.2 mg/kg dose over 10 [±2] seconds if needed) or propofol 2.0/1.0 mg/kg (i.e., 2.0 mg/kg IV slow injection over 30 [±5] seconds followed by an additional 1.0 mg/kg dose over 10 [±2]seconds if needed) in a blinded manner. Enrolled subjects will be stratified by American Society of Anesthesiologists Physical Status (ASA-PS; I-II and III-IV), age (\<65 and ≥65 years), and Body Mass Index (BMI \<35 and ≥35 kg/m2). Endotracheal intubation will be performed after adequate anesthetic induction (Modified Observer's Assessment of Awareness/Sedation [MOAA/S] ≤1) (Appendix 1) has been achieved and administration of neuromuscular blocking agent.

Before surgery, premedication is allowed except for sedative-hypnotic or analgesic drugs. Premedication should be recorded if used.

Prior to administration of the study drug in the operating room, the preoperative readiness of each subject will be confirmed. Oxygen will be supplied through a facemask (oxygen flow rate: ≥4 L/min) at least 2 minutes before study drug administration. Subsequently, the investigator can adjust the oxygen flow according to the specific situation of the subject and maintenance IV solution (normal saline [NS], lactated ringer's [LR], or 5% dextrose) will be administrated through IV infusion. Throughout the pre-induction and induction periods, a timing device must be used to allow accuracy and sequencing of necessary assessments.

02

Conditions studied

  • General Anesthesia
03

In context

Lead sponsor

Haisco-USA Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must satisfy all of the following criteria at the screening visit:

    1. Subjects undergoing elective surgery (non-emergency, non-cardiothoracic, and non-intracranial surgery anticipated to last at least 1 hour) requiring endotracheal intubation and inhalation general anesthesia during the maintenance period. Duration of surgery is defined as time from study drug administration to time of transfer from operating room to recovery room or PACU.
    2. Males or females, aged ≥18 years old, with I to IV (Appendix 6). For ASA-PS IV subjects, clinical status must be optimized at time of preoperative anesthesia evaluation per judgement of the anesthesiologist.
    3. ≥18 kg/m2.
    4. Vital signs at screening: RR ≥10 and ≤24 breaths/min; SpO2 ≥92% in ambient air; SBP ≥90 and ≤160 mmHg; DBP ≥55 and ≤ 100 mmHg; HR ≥55 (or ≥50 if subjects are on beta blockers) and ≤100 beats/min.
    5. For all women of , negative serum pregnancy test within the screening period and negative urine pregnancy test at baseline (Day 1). Additionally, women of childbearing potential* and male subjects with female partners of childbearing potential must agree to use as defined in 7.3.4 from the time of consent until 30 days post study drug administration.
    6. For subjects with known hypothyroidism and/or on thyroid-hormone replacement treatment (i.e., thyroxine), or subjects suspected to have thyroid dysfunction based on clinical laboratory and physical exam, a TSH must drawn and be within normal levels.
    7. Capable of understanding the procedures and methods of this study, willing to sign an Form (ICF), and able to complete this study in strict compliance with the study protocol.
    8. Willing to comply with the site's COVID guidelines and testing requirements as applicable.
    9. Patients with psychiatric/mental disorders must be considered stable on treatment (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) per investigator judgement, and no hospitalizations and urgent care due to the underlying psychiatric pathology for at least 12 months.

      • Women are considered of childbearing potential until becoming , unless she had a documented hysterectomy or bilateral oophorectomy / salpingo-oophorectomy. A woman is considered to be post-menopausal if she had no menses for at least 12 consecutive months (without an alternative medical cause).

Exclusion criteria

Exclusion Criteria:

  1. to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
  2. Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subjects having contraindications to propofol, opioids, and their antidotes. In cases where the only previous reaction to opioids was itching or nausea, subjects need not be excluded if the investigator believes the subject is not truly allergic to opioids.
  3. Medical condition or evidence of increased sedation/general anesthesia risk as follows:

    1. Cardiovascular disorder: uncontrolled hypertension (SBP >160 mmHg and/or DBP >100 mmHg) with or without antihypertensive therapy (antihypertensive therapy should be stable for 1 month prior to screening), serious arrhythmia (including the subjects with implanted pace makers), unstable heart failure, Adams-Stokes syndrome (i.e., syncope or near-syncope due to cardiac arrythmia), unstable angina, myocardial infarction occurring within 6 months prior to screening, history of tachycardia/bradycardia requiring medications, third degree atrioventricular block or corrected for HR using Fridericia's formula (QTcF) ≥450 ms for males and ≥470 ms for females.
    2. History of severe obstructive lung disease (i.e., [FEV1] \<50% predicted), history of bronchospasm requiring treatment in a hospital emergency room or hospitalization occurring within 3 months prior to screening, developing acute respiratory tract infection within 2 weeks prior to baseline (such as symptoms of fever, shortness of breath, wheezing, nasal congestion, and cough).
    3. Cerebrovascular disease: subject with a history of serious craniocerebral injury, convulsion, seizure disorder, intracranial hypertension, cerebral aneurysm, or stroke.
    4. Patients with psychiatric/mental disorders who have not been on a stable treatment regimen (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) per investigator judgement, for at least 12 months or who have been hospitalized or had emergent/urgent care due to the underlying psychiatric pathology within the last 12 months.
    5. Uncontrolled conditions of liver (e.g., severe hepatic insufficiency defined as Childs-Pugh class C), kidney, gastrointestinal tract, blood system, nervous system, or metabolic system diseases, judged by the investigator to be unsuitable for involvement in the study.
    6. History of uncontrolled diabetes in the opinion of the investigator.
    7. History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking >2 units of alcohol (1 unit = 360 mL of beer or 45 mL of spirit with a strength of 40% or 150 mL of wine).
    8. History of drug abuse that, in the opinion of the investigator, may confound the interpretation of safety or efficacy in a study subject.
    9. For subjects with known hypothyroidism and/or on thyroid-hormone replacement treatment (i.e., thyroxine), or subjects suspected to have thyroid dysfunction based on clinical laboratory and physical exam who has a TSH value outside the normal range.
  4. Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study as follows:

    1. Asthma must be stable: stable doses of asthma medications for the past 6 months, no requirement for rescue inhalers or oral within past 6 months, not evaluated in emergency department, urgent care, or hospitalized for an asthma attack within past 1 year.
    2. History (or family history) of malignant hyperthermia.
    3. Any previous failure of tracheal intubation.
    4. Judged to have a difficult airway for endotracheal intubation in the opinion of the Investigator based on parameters such as modified Mallampati score (Grade III or IV [Appendix 7]), neck mobility, short thyromental distance, and/or history of difficult intubation).
  5. Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics (e.g., benzodiazepines and opioids), taken within 5 half-lives prior to Day 1.
  6. Laboratory parameters measured at screening with the following levels:

    1. ≤1.5 x 109/L
    2. count \<80 x 109/L
    3. \<90 g/L (without blood transfusion within 14 days)
    4. and/or aspartate transaminase ≥2.0 x (ULN)
    5. Total ≥2.0 x ULN
    6. Severe renal impairment defined by (CrCl) ≤30 mL/min
  7. Female subjects with a positive pregnancy test at screening (serum) or baseline (urine); lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
  8. Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
465 participants (actual)

Study arms

  • Experimental
    HSK3486 for general anesthesia induction

    HSK3486 for induction of general anesthesia

    Drug: HSK3486

  • Active comparator
    Propofol for general anesthesia induction

    Propofol for induction of general anesthesia

    Drug: Propofol

Interventions

  • HSK3486 for induction of general anesthesia

  • Propofol for induction of general anesthesia

    Also known as: Diprivan

06

What researchers measure

Primary outcomes

  1. Success Rate of General Anesthesia Induction

    1. Induction success (MOAA/S ≤1) after administration of the study drug, and 2. One or less top-up doses required without using any rescue drugs.

    Time frame: From the time of study drug administration to desired depth of anesthesia to MOAA/S≤1( up to 5 minutes)

Secondary outcomes

  1. Percentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression

    The outcome is defined by all the following conditions: a) Desired depth of anesthesia for general elective surgery is defined if all following criteria are met: i) No clinical signs of inadequate depth of anesthesia, such as lacrimation, movement, vomiting, coughing, laryngospasm, bucking, swallowing reflex or bronchospasm etc. ii) No blood pressure (SBP, DBP, or MAP) increases more than 20% from baseline in response to any major operational procedures or noxious stimulus in defined period. iii) Subjects maintain desired depth of anesthesia for general elective surgery with BIS as an objective assessment (after reaching initial lowest value, BIS remains sustainable level at not more than 60). b) No significant respiratory depression, such as apnea, prior to the administration of rocuronium bromide. c) No significant cardiac depression indicated by blood pressure decrease that requires intervention, i.e., vasopressors and/or IV fluid resuscitation.

    Time frame: 15 minutes from end of drug administration

  2. Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥1

    0 = No Pain 1-3 = Mild Pain 4-6 = Moderate Pain 7-9 = Severe Pain 10 = Worst pain imaginable

    Time frame: From start of the drug administration to MOAA/S ≤1 (up to 3 minutes)

07

Results

Posted Aug 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneHSK3486Propofol
Started313152
Dosed300145
Full analysis set300145
Safety set300145
Completed300145
Not completed137

Outcome measures

PrimarySuccess Rate of General Anesthesia Induction

1. Induction success (MOAA/S ≤1) after administration of the study drug, and 2. One or less top-up doses required without using any rescue drugs.

Time frame:
From the time of study drug administration to desired depth of anesthesia to MOAA/S≤1( up to 5 minutes)
Reported as:
Count of participants · Participants
Success Rate of General Anesthesia Induction
ParticipantsHSK3486Propofol
Success Rate of General Anesthesia Induction298143
SecondaryPercentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression

The outcome is defined by all the following conditions: a) Desired depth of anesthesia for general elective surgery is defined if all following criteria are met: i) No clinical signs of inadequate depth of anesthesia, such as lacrimation, movement, vomiting, coughing, laryngospasm, bucking, swallowing reflex or bronchospasm etc. ii) No blood pressure (SBP, DBP, or MAP) increases more than 20% from baseline in response to any major operational procedures or noxious stimulus in defined period. iii) Subjects maintain desired depth of anesthesia for general elective surgery with BIS as an objective assessment (after reaching initial lowest value, BIS remains sustainable level at not more than 60). b) No significant respiratory depression, such as apnea, prior to the administration of rocuronium bromide. c) No significant cardiac depression indicated by blood pressure decrease that requires intervention, i.e., vasopressors and/or IV fluid resuscitation.

Time frame:
15 minutes from end of drug administration
Reported as:
Count of participants · Participants
Percentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression
ParticipantsHSK3486 for General Anesthesia InductionPropofol for General Anesthesia Induction
Percentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression8145
SecondaryProportion of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥1

0 = No Pain 1-3 = Mild Pain 4-6 = Moderate Pain 7-9 = Severe Pain 10 = Worst pain imaginable

Time frame:
From start of the drug administration to MOAA/S ≤1 (up to 3 minutes)
Reported as:
Count of participants · Participants
Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥1
ParticipantsHSK3486 for General Anesthesia InductionPropofol for General Anesthesia Induction
Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥15686

Adverse events

Collected over AEs will be collected from the time of informed consent until the final study visit (Day 8). A treatment-emergent AE is defined as: an AE that occurs after the subject starts treatment with the IMP. If an Investigator becomes aware of a serious adverse event within 30 days after the last dose of study drug and it is considered by him/her to be caused by the study drug with a reasonable possibility, the event must be documented and reported.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HSK3486 for General Anesthesia Induction1/300 (0.3%)5/300 (1.7%)185/300 (61.7%)
Propofol for General Anesthesia Induction0/145 (0%)1/145 (0.7%)96/145 (66.2%)
Most frequent serious events
Most frequent serious events
EventHSK3486 for General Anesthesia InductionPropofol for General Anesthesia Induction
Mediastinal hematomaRespiratory, thoracic and mediastinal disorders0/3001/145
Confusional statePsychiatric disorders1/3000/145
CholelithiasisHepatobiliary disorders1/3000/145
Urecteric injuryInjury, poisoning and procedural complications1/3000/145
Internal hemorrhageVascular disorders1/3000/145
Wound dehiscenceInfections and infestations1/3000/145
PeritonitisInfections and infestations1/3000/145
Septic ShockInfections and infestations1/3000/145
Most frequent other events
Showing 10 of 11
Most frequent other events
EventHSK3486 for General Anesthesia InductionPropofol for General Anesthesia Induction
HypotensionVascular disorders55/30032/145
NauseaGastrointestinal disorders48/30017/145
Procedural HypotensionInjury, poisoning and procedural complications34/30023/145
HypertensionVascular disorders24/3009/145
ConstipationNervous system disorders3/30010/145
TachycardiaCardiac disorders13/3007/145
Procedural PainInjury, poisoning and procedural complications9/3006/145
HaematuriaRenal and urinary disorders4/3006/145
Procedural nauseaInjury, poisoning and procedural complications4/3005/145
Electrocardiogram QT prolongedInvestigations2/3005/145

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)HSK3486 for General Anesthesia InductionPropofol for General Anesthesia InductionTotal
<=18 years000
Between 18 and 65 years229110339
>=65 years7135106
Sex: Female, Male
Sex: Female, Male(Participants)HSK3486 for General Anesthesia InductionPropofol for General Anesthesia InductionTotal
Female17374247
Male12771198
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HSK3486 for General Anesthesia InductionPropofol for General Anesthesia InductionTotal
Hispanic or Latino9138129
Not Hispanic or Latino204107311
Unknown or Not Reported505
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HSK3486 for General Anesthesia InductionPropofol for General Anesthesia InductionTotal
American Indian or Alaska Native314
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American382361
White254114368
More than one race033
Unknown or Not Reported246
Region of Enrollment
Region of Enrollment(participants)HSK3486 for General Anesthesia InductionPropofol for General Anesthesia InductionTotal
United States234119353
Poland271542
Spain391150
ASA-PS
ASA-PS(Participants)HSK3486 for General Anesthesia InductionPropofol for General Anesthesia InductionTotal
ASA-PS I472471
ASA-PS II18390273
ASA-PS III7031101
BMI
BMI(Participants)HSK3486 for General Anesthesia InductionPropofol for General Anesthesia InductionTotal
<35kg/m^2237113350
≥35kg/m^2633295
08

Study locations

28 sites
  • North Alabama Medical Center
    Florence, Alabama 35630, United States
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Gulfcoast Research Institute
    Sarasota, Florida 34232, United States
  • Phoenix Clinical Research, LLC
    Tamarac, Florida 33321, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • EBGS Clinical Research Center
    Snellville, Georgia 30078, United States
  • University of Iowa Hospitals and Clinics (Dept of Anesthesia)
    Iowa City, Iowa 52242, United States
  • U of L Health, University of Louisville Hospital
    Louisville, Kentucky 40202, United States
  • The Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • M3-Emerging Medical Research, LLC
    Durham, North Carolina 27704, United States
  • Duke University Medical Center (DUMC)
    Durham, North Carolina 27710, United States
  • The Ohio State University Wexner Medical Center - University Hospital
    Columbus, Ohio 43210, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Memorial Hermann Village
    Houston, Texas 77043, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • Endeavor Clinical Trials, LLC
    San Antonio, Texas 78240, United States
  • Uniwersytecki Szpital Kliniczny W Opolu
    Opole, Poland
  • Państwowy Instytut Medyczny Mswia - Klinika Anestezjologii I Intensywnej Terapii
    Warsaw, Poland
  • Spsk Nr 1 Im. Prof. S. Szyszko
    Zabrze, Poland
  • Hospital Clinic De Barcelona
    Barcelona, Spain
  • Hospital General Universitario De Ciudad Real
    Ciudad Real, Spain
  • Universidad de Navarra - Clinica Universidad de Navarra en Pamplona
    Pamplona, Spain
  • Hospital Clinico Universitario de Valencia (CHUV)
    Valencia, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jul 2024, 6 months.

Results were first posted in Aug 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 3, 2022
StartActual
Jan 12, 2024
Primary completionActual
Jul 23, 2024
CompletionActual
Jul 23, 2024
Results first posted
Aug 11, 2025
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05486416
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Jan 12, 2024
Primary completion
Jul 23, 2024
Completion
Jul 23, 2024
Results posted
Aug 11, 2025
Last update
Oct 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion